( HAYWARD Calif. April 10 2007 /PRNew...)Kosan Announces Data Presentations at Upcoming AACR Annual Meeting,Health

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, April 14-18, 2007.

Poster presentations on Kosan's programs are as follows. The location for all poster presentations is the Los Angeles Convention Center Exhibit Hall.

    Date   Abstract #   Title             Session          Poster  Poster #

                                                           Section

    4/15

    1:00-  1544         Tanespimycin:     Experimental     32      4

    5:00                 No effects on     and Molecular

                         QTC interval      Therapeutics 13

                         using two

                         formulations


    4/15

    1:00-  1568         Preclinical       Experimental     32      28

    5:00                 safety profile    and Molecular

                         of tanespimycin   Therapeutics 13

                         (KOS-5: 953) --

                         a heat shock

                         protein 90

                         (Hsp90)

                         inhibitor


    4/15

    1:00-  1438         KOS-1803: A new,  Experimental     27      19

    5:00                 rationally        and Molecular

                         designed          Therapeutics 8

                         epothilone

                         analog with an

                         improved

                         pharmacological

                         profile and

                         efficacy in

                         xenograft mouse

                         models


    4/18

    8:00-  5597         Anti-tumor        Experimental     29      2

    12:00                activity of       and Molecu
'"/>




Page: 1 2 3 
Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel
Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On
Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial